HILLEVAX INC (HLVX)
US43157M1027 - Common Stock
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
HLVX Stock Earnings: HilleVax Misses EPS for Q2 2024
HLVX stock results show that HilleVax missed analyst estimates for earnings per share the second quarter of 2024.
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
HilleVax Announces Reduction in Force
HilleVax Announces Reduction in Force
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
GRFS Stock Alert: Grifols Pops 20% on Takeover Interest
Grifols stock is up on Monday as the founding family of the company has presented a preliminary takeover offer for GRFS shares.
Why Is HilleVax (HLVX) Stock Down 87% Today?
HilleVax stock is down on Monday after HLVX investors learned of a failed Phase 2b clinical trial of its norovirus vaccine for infants.
HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in...
HLVX Stock Earnings: HilleVax Misses EPS for Q1 2024
HLVX stock results show that HilleVax missed analyst estimates for earnings per share the first quarter of 2024.
HLVX Stock Earnings: HilleVax Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HilleVax (NASDAQ:HLVX) just reported results for the first quarter of 2024.Hill...
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
HilleVax Becomes Oversold (HLVX)
HLVX Crosses Below Key Moving Average Level
HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023
HLVX stock results show that HilleVax beat analyst estimates for earnings per share the fourth quarter of 2023.
HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HilleVax (NASDAQ:HLVX) just reported results for the fourth quarter of 2023.Hil...
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 ...
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...